Trial Profile
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon-alfa-2b, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2015
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 10 Nov 2015 New trial record